Is EQ or CNTX more profitable?

Equillium's return on equity of -41.15% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -41.15% -38.29% Context Therapeutics N/A -82.06% -72.74%

Does the media prefer EQ or CNTX?

In the previous week, Equillium had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 4 mentions for Equillium and 2 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.91 beat Equillium's score of 0.31 indicating that Context Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IMDX or CNTX?

In the previous week, Oncocyte had 4 more articles in the media than Context Therapeutics. MarketBeat recorded 6 mentions for Oncocyte and 2 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.91 beat Oncocyte's score of 0.29 indicating that Context Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncocyte 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, HURA or CNTX?

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TuHURA Biosciences N/A N/A -$30.05M -$0.54 N/A Context Therapeutics N/A N/A -$36.12M -$0.48 N/A

Is HURA or CNTX more profitable?

Context Therapeutics' return on equity of -82.06% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.47% -106.98% Context Therapeutics N/A -82.06% -72.74%

Does the media refer more to HURA or CNTX?

In the previous week, TuHURA Biosciences and TuHURA Biosciences both had 2 articles in the media. TuHURA Biosciences' average media sentiment score of 1.71 beat Context Therapeutics' score of 0.91 indicating that TuHURA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, CNTX or BMEA?

Biomea Fusion is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.48 N/A Biomea Fusion N/A N/A -$61.80M -$0.29 N/A

Is CNTX or BMEA more profitable?

Context Therapeutics' return on equity of -82.06% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% Biomea Fusion N/A -253.73% -97.91%

Does the media favor CNTX or BMEA?

In the previous week, Biomea Fusion had 14 more articles in the media than Context Therapeutics. MarketBeat recorded 16 mentions for Biomea Fusion and 2 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.91 beat Biomea Fusion's score of 0.48 indicating that Context Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biomea Fusion 2 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, CNTX or CRBP?

Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.48 N/A Corbus Pharmaceuticals N/A N/A -$78.54M -$6.19 N/A

Is CNTX or CRBP more profitable?

Context Therapeutics' return on equity of -82.06% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% Corbus Pharmaceuticals N/A -87.05% -74.22%

Context Therapeutics (CNTX) Competitors

$0.35 -0.02 (-5.69%)

As of 02:23 PM Eastern

Compare

CNTX vs. EQ, IMDX, HURA, BMEA, and CRBP

Should you buy Context Therapeutics stock or one of its competitors? Context Therapeutics's main competitors and comparable companies include Equillium (EQ), Oncocyte (IMDX), TuHURA Biosciences (HURA), Biomea Fusion (BMEA), and Corbus Pharmaceuticals (CRBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Context Therapeutics compare to Equillium?

Equillium (NASDAQ:EQ) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

Equillium's return on equity of -41.15% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-41.15%	-38.29%
Context Therapeutics	N/A	-82.06%	-72.74%

Equillium has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market.

Equillium currently has a consensus target price of $7.57, indicating a potential upside of 352.03%. Context Therapeutics has a consensus target price of $6.17, indicating a potential upside of 1,661.90%. Given Context Therapeutics' higher probable upside, analysts clearly believe Context Therapeutics is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

27.1% of Equillium shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 17.8% of Equillium shares are owned by insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Equillium has higher revenue and earnings than Context Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	2.58	-$22.40M	-$0.20	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

In the previous week, Equillium had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 4 mentions for Equillium and 2 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.91 beat Equillium's score of 0.31 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Equillium beats Context Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Context Therapeutics compare to Oncocyte?

Oncocyte (NASDAQ:IMDX) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, Oncocyte had 4 more articles in the media than Context Therapeutics. MarketBeat recorded 6 mentions for Oncocyte and 2 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.91 beat Oncocyte's score of 0.29 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncocyte	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

55.4% of Oncocyte shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 2.2% of Oncocyte shares are held by company insiders. Comparatively, 4.8% of Context Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Context Therapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
Context Therapeutics	N/A	-82.06%	-72.74%

Oncocyte currently has a consensus target price of $10.50, suggesting a potential upside of 169.58%. Context Therapeutics has a consensus target price of $6.17, suggesting a potential upside of 1,661.90%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Context Therapeutics is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Context Therapeutics has lower revenue, but higher earnings than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	31.47	-$50.22M	-$1.49	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

Oncocyte has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

Summary

Context Therapeutics beats Oncocyte on 10 of the 15 factors compared between the two stocks.

How does Context Therapeutics compare to TuHURA Biosciences?

TuHURA Biosciences (NASDAQ:HURA) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

Context Therapeutics' return on equity of -82.06% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.47%	-106.98%
Context Therapeutics	N/A	-82.06%	-72.74%

In the previous week, TuHURA Biosciences and TuHURA Biosciences both had 2 articles in the media. TuHURA Biosciences' average media sentiment score of 1.71 beat Context Therapeutics' score of 0.91 indicating that TuHURA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 6.1% of TuHURA Biosciences shares are owned by insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

TuHURA Biosciences has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market.

TuHURA Biosciences currently has a consensus target price of $9.00, indicating a potential upside of 326.74%. Context Therapeutics has a consensus target price of $6.17, indicating a potential upside of 1,661.90%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than TuHURA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

Context Therapeutics beats TuHURA Biosciences on 9 of the 12 factors compared between the two stocks.

How does Context Therapeutics compare to Biomea Fusion?

Context Therapeutics (NASDAQ:CNTX) and Biomea Fusion (NASDAQ:BMEA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Context Therapeutics presently has a consensus target price of $6.17, indicating a potential upside of 1,661.90%. Biomea Fusion has a consensus target price of $9.00, indicating a potential upside of 574.16%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by company insiders. Comparatively, 10.6% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Context Therapeutics has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market.

Context Therapeutics' return on equity of -82.06% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
Biomea Fusion	N/A	-253.73%	-97.91%

In the previous week, Biomea Fusion had 14 more articles in the media than Context Therapeutics. MarketBeat recorded 16 mentions for Biomea Fusion and 2 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.91 beat Biomea Fusion's score of 0.48 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biomea Fusion	2 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biomea Fusion is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.29	N/A

Summary

Context Therapeutics beats Biomea Fusion on 9 of the 13 factors compared between the two stocks.

How does Context Therapeutics compare to Corbus Pharmaceuticals?

Context Therapeutics (NASDAQ:CNTX) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Context Therapeutics has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.63, meaning that its share price is 163% more volatile than the broader market.

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Context Therapeutics had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 2 mentions for Context Therapeutics and 1 mentions for Corbus Pharmaceuticals. Context Therapeutics' average media sentiment score of 0.91 beat Corbus Pharmaceuticals' score of 0.68 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Context Therapeutics	Positive
Corbus Pharmaceuticals	Positive

Context Therapeutics' return on equity of -82.06% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%

Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A

Context Therapeutics presently has a consensus target price of $6.17, indicating a potential upside of 1,661.90%. Corbus Pharmaceuticals has a consensus target price of $41.00, indicating a potential upside of 477.46%. Given Context Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Context Therapeutics is more favorable than Corbus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Context Therapeutics beats Corbus Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

Get Context Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTX vs. The Competition

Export

Metric	Context Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$32.16M	$3.91B	$7.25B	$13.16B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.73	14.06	274.69	25.81
Price / Sales	N/A	1,318.94	681.05	110.54
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.53	15.30	10.45	6.32
Net Income	-$36.12M	-$22.86M	$3.48B	$359.77M
7 Day Performance	-4.92%	-3.03%	-1.33%	-0.15%
1 Month Performance	-19.61%	-9.12%	-4.58%	-4.08%
1 Year Performance	-61.24%	31.34%	16.32%	6.16%

Context Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTX Context Therapeutics	2.8276 of 5 stars	$0.35 -5.7%	$6.17 +1,661.9%	-61.1%	$32.16M	N/A	N/A	15
EQ Equillium	2.1137 of 5 stars	$2.05 -2.6%	$7.57 +270.2%	+19.4%	$129.73M	N/A	N/A	40
IMDX Oncocyte	1.8695 of 5 stars	$3.96 -1.6%	$10.50 +165.5%	N/A	$129.42M	$1.67M	N/A	120	Positive News
HURA TuHURA Biosciences	1.7568 of 5 stars	$2.02 -1.5%	$9.00 +345.5%	-18.3%	$128.74M	N/A	N/A	N/A
BMEA Biomea Fusion	2.0314 of 5 stars	$1.76 -1.4%	$9.00 +412.8%	-27.7%	$127.21M	N/A	N/A	50	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTX) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Context Therapeutics (CNTX) Competitors

CNTX vs. EQ, IMDX, HURA, BMEA, and CRBP

How does Context Therapeutics compare to Equillium?

Summary

How does Context Therapeutics compare to Oncocyte?

Summary

How does Context Therapeutics compare to TuHURA Biosciences?

Summary

How does Context Therapeutics compare to Biomea Fusion?

Summary

How does Context Therapeutics compare to Corbus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX vs. The Competition

Context Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Context Therapeutics (CNTX) Competitors

CNTX vs. EQ, IMDX, HURA, BMEA, and CRBP

How does Context Therapeutics compare to Equillium?

Is EQ or CNTX more profitable?

Which has more risk and volatility, EQ or CNTX?

Do analysts rate EQ or CNTX?

Do insiders and institutionals have more ownership in EQ or CNTX?

Which has preferable valuation and earnings, EQ or CNTX?

Does the media prefer EQ or CNTX?

Summary

How does Context Therapeutics compare to Oncocyte?

Does the media prefer IMDX or CNTX?

Do insiders and institutionals hold more shares of IMDX or CNTX?

Is IMDX or CNTX more profitable?

Do analysts recommend IMDX or CNTX?

Which has higher valuation & earnings, IMDX or CNTX?

Which has more volatility & risk, IMDX or CNTX?

Summary

How does Context Therapeutics compare to TuHURA Biosciences?

Which has higher earnings and valuation, HURA or CNTX?

Is HURA or CNTX more profitable?

Does the media refer more to HURA or CNTX?

Do insiders & institutionals believe in HURA or CNTX?

Which has more risk & volatility, HURA or CNTX?

Do analysts rate HURA or CNTX?

Summary

How does Context Therapeutics compare to Biomea Fusion?

Do analysts recommend CNTX or BMEA?

Do institutionals and insiders believe in CNTX or BMEA?

Which has more risk & volatility, CNTX or BMEA?

Is CNTX or BMEA more profitable?

Does the media favor CNTX or BMEA?

Which has better valuation & earnings, CNTX or BMEA?

Summary

How does Context Therapeutics compare to Corbus Pharmaceuticals?

Which has more risk & volatility, CNTX or CRBP?

Do insiders and institutionals believe in CNTX or CRBP?

Does the media prefer CNTX or CRBP?

Is CNTX or CRBP more profitable?

Which has preferable valuation and earnings, CNTX or CRBP?

Do analysts recommend CNTX or CRBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX vs. The Competition

Context Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools